Candid Therapeutics Acquired by UCB | Healthcare M&A Deal

UCB has acquired Candid Therapeutics, a healthcare services other business in the United States, for $2.2 billion. Candid Therapeutics focuses on immunology and specialty therapeutics development, supporting UCB’s pipeline expansion in key immune-mediated areas. UCB acquisitions in healthcare M&A aim to strengthen late-stage and platform capabilities, with Candid Therapeutics acquisition adding product and research depth. The platform acquisition is a strategic acquisition by a strategic buyer, sized over $100M, and is currently announced with deal terms and timing subject to customary closing conditions.